Last updated on February 2018

Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)


Brief description of study

This is a multi-centre, multi-national, prospective, observational study of Friedreich's Ataxia (FRDA) with a control group to:

  • obtain natural history data on individuals affected by FRDA
  • relate clinical assessments and results from proteomic analyses
  • expedite identification and recruitment of participants for clinical trials
  • develop and validate sensitive and reliable outcome measures for detecting onset and change over the natural course of FRDA which may also be potential outcome measures for use in future clinical trials and clinical care
  • plan for future research studies

Detailed Study Description

The EFACTS patient registry integrates prospectively and systematically collected clinical research data (e.g. clinical tests, demographical characteristics) with access to biological specimens (e.g. blood, urine) obtained from individuals with genetically confirmed FRDA and unrelated control research participants.

The EFACTS patient registry started out as a 4-year study and is currently running without a set end date. Eligible subjects are assessed at annual study visits on the clinical symptoms and signs of the disease. At each study visit, general clinical, motor function, cognitive, and Quality of Life assessments are administered. In addition, participants are providing bio samples for the purposes of genetic testing and for research to identify valuable biomarkers of FRDA. Biological specimens and clinical data are made available to qualified scientists within the EFACTS network whose projects are reviewed and approved by the EFACTS Steering Committee. Research projects should aim to advance scientific knowledge towards establishing clinically effective treatments that delay onset and/or slow the progression of the disease.

Clinical Study Identifier: NCT02069509

Contact Investigators or Research Sites near you

Start Over

Sylvia Boesch, MD

Medical University Innsbruck, Department of Neurology
Innsbruck, Austria
  Connect »

Massimo Pandolfo, MD

Universit Libre de Bruxelles
Bruxelles, Belgium
  Connect »

Alexandra Dürr, PhD

H pital Piti Salp tri re
Paris, France
  Connect »

Mathieu Anheim, MD

H ptal de Hautepierre, Department of Neurology
Strasbourg, France
  Connect »

Jörg B. Schulz, MD

University Hospital Aachen, Dept. of Neurology
Aachen, Germany
  Connect »

Thomas Klockgether, MD

University Hospital Bonn, Dept. of Neurology
Bonn, Germany
  Connect »

Katrin Bürk, MD

Philipps University Marburg, Dept. of Neurology
Marburg, Germany
  Connect »

Thomas Klopstock, MD

University of Munich, Dept. of Neurology
Munich, Germany
  Connect »

Ludger Schöls, MD

University of T bingen, Dept. of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research
Tübingen, Germany
  Connect »

Caterina Mariotti, MD

Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
  Connect »

Francisco J. Rodriguez de Rivera ...

Hospital Universitario La Paz, Servicio de Neurologia
Madrid, Spain
  Connect »

Paola Giunti, MD

University College of London, Institute of Neurology
London, United Kingdom
  Connect »